Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 13/20 | 0.35 |
| ▸ | MGLL | Q99685 | 1/20 | 0.33 |
| ▸ | MTOR | P42345 | 2/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
| ▸ | BCHE | P06276 | 2/20 | 0.32 |
| ▸ | ACHE | P22303 | 2/20 | 0.32 |
| ▸ | LIPE | Q05469 | 2/20 | 0.32 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.31 |
| ▸ | AKT1 | P31749 | 1/20 | 0.31 |
| ▸ | AKT2 | P31751 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25753038 | 0.64 | BRD4 (0.39) | ROCK1AKT1AKT2 | |
| SCHEMBL24088572 | 0.64 | KCNH2 (0.38) | ROCK2MTORPIK3CAAKT1AKT2 | |
| SCHEMBL23780346 | 0.62 | GPR35 (0.44) | GPR35ROCK2MTORPIK3CAROCK1 | |
| Trimethylammonium SCHEMBL27558428 | 0.59 | ALDH1A1 (0.44) | GPR35ROCK2ROCK1 | |
| SCHEMBL30301433 | 0.58 | ROCK2 (0.32) | ROCK2MTORPIK3CA | |
| SCHEMBL731315 | 0.57 | ROCK2 (0.47) | ROCK2ROCK1 | |
| SCHEMBL21856149 | 0.57 | CLCN2 (0.41) | GPR35ROCK2ROCK1AKT1AKT2 | |
| SCHEMBL21359417 | 0.57 | MCL1 (0.47) | GPR35ROCK2ROCK1AKT1AKT2 | |
| SCHEMBL3506781 | 0.56 | AKT1 (0.48) | GPR35ROCK2ROCK1AKT1AKT2 | |
| SCHEMBL30110398 | 0.56 | POLQ (0.47) | GPR35ROCK2ROCK1AKT1AKT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210278408-A1 | METHODS OF TREATMENT OF CANCER WITH SUBSTITUTED PYRROLE AND PYRAZOLE COMPOUNDS AND DIAGNOSIS OF CANCERS SUSCEPTIBLE TO TREATMENT WITH SUBSTITUTED PYRROLE AND PYRAZOLE COMPOUNDS | BANTAM PHARMACEUTICAL LLC (US) | 2021-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210278408-A1 | METHODS OF TREATMENT OF CANCER WITH SUBSTITUTED PYRROLE AND PYRAZOLE COMPOUNDS AND DIAGNOSIS OF CANCERS SUSCEPTIBLE TO TREATMENT WITH SUBSTITUTED PYRROLE AND PYRAZOLE COMPOUNDS | TP53, MKI67, VHL | GPR35 3233/4885ROCK2 3627/4885MGLL 4805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.